AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preclinical data published on how Panzem inhibits cell growth.
2003 FEB 13 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc., (ENMD) has published preclinical data on how its small molecule drug candidate Panzem inhibits the growth of tumor cells and blood vessel cells associated with disease.
EntreMed scientists found that Panzem, also referred to as 2-methoxyestradiol (or 2ME2), kills tumor cells and their supporting blood vessel cells by turning-on increased levels of a death receptor (Death Receptor 5 or DR5) that is located on the cell surface. In turn, this action triggers programmed cell death, or "apoptosis." DR5 may also serve as surrogate marker for assessing clinical responses to Panzem. Currently, Panzem is in phase I clinical trials for breast cancer and in phase II trials for the blood cancer multiple myeloma. A phase II trial for prostate cancer is complete. The in vitro and in vivo Panzem data were published in Cancer Research.
EntreMed president and chief operating officer Neil Campbell said, "Identifying and understanding how Panzem activates cell death is critical to EntreMed's further development of Panzem not only for an oncology treatment, but also for non-oncology applications in such fields as ...
- Entremed AACR Studies Reveal Panzem(R)'s Action and Support Further Clinical...
- Press release article from: PR Newswire July 14, 2003 700+ words
...data produced from a third Panzem(R) preclinical study presented...LaVallee, co-authored the three Panzem(R) studies presented at...Caspase-3 Activation and Death Receptor-5 (DR5) Up-Regulation...School of Medicine. About Panzem(R) Panzem(R) [2-methoxyestradiol...
- EntreMed Announces Presentation for Phase 2 Results for Panzem(R) Capsules in...
- Press release article from: M2 Presswire June 5, 2007 700+ words
...patients continue to receive Panzem Capsules, including three...multiple myeloma from the FDA. Panzem is an orally-active small...mechanism is the upregulation of death receptor 5 (DR5) leading to apoptosis. Panzem also reduces levels of IL...
- Preclinical data published on how Panzem inhibits cell growth.
- Newspaper article from: Pharma Business Week February 10, 2003 700+ words
...EntreMed scientists found that Panzem, also referred to as 2-methoxyestradiol...turning-on increased levels of a death receptor (Death Receptor 5 or DR5) that...for assessing clinical responses to Panzem. Currently, Panzem is in phase...
- EntreMed Scientists Publish Preclinical Data on How Panzem(TM) Inhibits Cell...
- Press release article from: PR Newswire January 15, 2003 700+ words
...EntreMed scientists found that Panzem(TM), also referred to as 2...turning-on increased levels of a death receptor (Death Receptor 5 or DR5) that...for assessing clinical responses to Panzem(TM). Currently, Panzem(TM...
- EntreMed Presents Phase 2 Results for Panzem(R) Capsules in Multiple Myeloma.
- Press release article from: PR Newswire June 4, 2007 700+ words
...patients continue to receive Panzem(R) Capsules, including...multiple myeloma from the FDA. Panzem(R) is an orally-active...mechanism is the upregulation of death receptor 5 (DR5) leading to apoptosis. Panzem(R) also reduces levels...
- EntreMed Scientists publish pre-clinical data on how Panzem inhibits cell...
- News wire article from: Asia Africa Intelligence Wire January 15, 2003 700+ words
...EntreMed scientists found that Panzem, also referred to as 2-methoxyoestradiol...turning-on increased levels of a death receptor (Death Receptor 5 or DR5) that...for assessing clinical responses to Panzem. Currently, Panzem is in Phase...
- EntreMed Selects Panzem(R) Formulation.
- Press release article from: PR Newswire September 30, 2003 700+ words
...has selected the final formulations of Panzem(R), EntreMed's lead drug candidate...expects to transition the reformulated Panzem(R) into new clinical trials in early...are designed to increase the amount of Panzem(R) that circulates in the patient...
- EntreMed's New Panzem(R) Formulations Increase Tumor Inhibition In Preclinical...
- Press release article from: PR Newswire November 20, 2003 700+ words
...demonstrating that its new formulations of Panzem(R) have increased antitumor activity...bioavailability, leading to higher blood levels of Panzem(R) after oral dosing in preclinical...maintained with no evidence of new toxicities. Panzem(R), the Company's lead drug candidate...
- Preclinical data supports Panzem application for osteoporosis.
- Magazine article from: Women's Health Weekly March 27, 2003 700+ words
...published a preclinical study demonstrating Panzem's potential use in preventing and treating...postmenopausal women. In this preclinical study, Panzem compared favorably with other accepted...the March 2003 issue of Endocrinology. Panzem, EntreMed's lead small molecule drug...
- EntreMed Preclinical Data Supports Panzem(TM) Application For Osteoporosis.
- Press release article from: PR Newswire February 24, 2003 700+ words
...published a preclinical study demonstrating Panzem(TM)'s potential use in preventing...postmenopausal women. In this preclinical study, Panzem(TM) compared favorably with other accepted...cgi-bin/prnh/20010620/ENMDLOGO ) Panzem(TM), EntreMed's lead small molecule...
Source: HighBeam Research, Preclinical data published on how Panzem inhibits cell growth.